Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Highlights

Highlights February 2017 In This Issue Volume 177, Number 2 Pages 149-296 JAMA Internal Medicine Research Opinion Viewpoint Fish Oil and Aspirin for AVF Failure in Hemodialysis 184 155 | HEALTH CARE POLICY AND LAW The FAVOURED trial (Fish Oils and Aspirin in Vascular Access Outcomes in Renal Disease) The Use of Public Health Evidence is the fi rst randomized clinical trial to determine whether fi sh oil or low-dose aspirin is in Whole Woman’s Health v Hellerstedt eff ective in preventing failure of de novo arteriovenous fi stulae (AVF) in patients requiring D Grossman hemodialysis. In this trial that included 567 adults, the occurrence of fi stula failure within 157 | HEALTH CARE POLICY AND LAW 12 months of surgery was high (47%) and not reduced by fi sh oil (relative risk 1.03) or Promotion of Drugs for Off -label Uses: The US Food and Drug Administration aspirin (relative risk 1.05) compared with placebo. Based on these results, neither fi sh oil at a Crossroads nor aspirin can be recommended for prevention of AVF failure and additional strategies to J Kim and A Kapczynski reduce the high AVF failure rate are urgently required. 159 Transcatheter Aortic Valve Editor’s Note http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Highlights

JAMA Internal Medicine , Volume 177 (2) – Feb 1, 2017
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/highlights-cJ5vJFbY84

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright 2017 American Medical Association. All Rights Reserved.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/jamainternmed.2016.6129
Publisher site
See Article on Publisher Site

Abstract

February 2017 In This Issue Volume 177, Number 2 Pages 149-296 JAMA Internal Medicine Research Opinion Viewpoint Fish Oil and Aspirin for AVF Failure in Hemodialysis 184 155 | HEALTH CARE POLICY AND LAW The FAVOURED trial (Fish Oils and Aspirin in Vascular Access Outcomes in Renal Disease) The Use of Public Health Evidence is the fi rst randomized clinical trial to determine whether fi sh oil or low-dose aspirin is in Whole Woman’s Health v Hellerstedt eff ective in preventing failure of de novo arteriovenous fi stulae (AVF) in patients requiring D Grossman hemodialysis. In this trial that included 567 adults, the occurrence of fi stula failure within 157 | HEALTH CARE POLICY AND LAW 12 months of surgery was high (47%) and not reduced by fi sh oil (relative risk 1.03) or Promotion of Drugs for Off -label Uses: The US Food and Drug Administration aspirin (relative risk 1.05) compared with placebo. Based on these results, neither fi sh oil at a Crossroads nor aspirin can be recommended for prevention of AVF failure and additional strategies to J Kim and A Kapczynski reduce the high AVF failure rate are urgently required. 159 Transcatheter Aortic Valve Editor’s Note

Journal

JAMA Internal Medicine – American Medical Association

Published: Feb 1, 2017

There are no references for this article.